Director, Preclinical Theranostics Program
Highly specific and potent in vivo immuno-targeting has previously been limited to targeting of cell surface proteins. I have led the successful development of a technology that enables targeting antigens secreted by luminal tissues, opening a new class of cancer tissue-specific targets including widely used circulating biomarkers. Previous discoveries have shown that the neonatal fc-receptor (FcRn) selectively traffics IgG1 /antigen complexes from the exterior of the cell to lysosome compartments, while unbound IgG1 are released back into the blood circulation. I have, together with my collaborators, demonstrated that this immunological process can be utilized for in vivo targeting by using antibodies against proteins produced by tumorous or healthy tissue.
Sunday, May 5
3:35 PM – 3:43 PM